2020 WHO Classification of Female Genital Tumors

Höhn, Anne Kathrin; Brambs, Christine; Hiller, Grit Gesine Ruth; May, Doris; Schmoeckel, Elisa; Horn, Lars‐Christian

doi:10.1055/a-1545-4279

Cited by 140 publications

(116 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although there is growing evidence that ACs have different epidemiology, prognostic variables, patterns of dissemination, and treatment failure following therapy compared to SCCs, both are staged and treated similarly ( 47 ). Silvaclassification, which stratifies invasion in three patterns, is used to determine HPV-related CAC ( 47 , 48 ). Even though p16 expression is considered to be a surrogate marker for HPVassociation, p16 IHC testing is not absolutely necessary for the classification, and HPV analysisis not necessary for the diagnosis ( 48 ).…”

Section: Hpv Attributes Screening Diagnosis Treatment and Preventionmentioning

confidence: 99%

“…Silvaclassification, which stratifies invasion in three patterns, is used to determine HPV-related CAC ( 47 , 48 ). Even though p16 expression is considered to be a surrogate marker for HPVassociation, p16 IHC testing is not absolutely necessary for the classification, and HPV analysisis not necessary for the diagnosis ( 48 ). HPV-related CSCC causes pre-cancerous lesions but there is no known precancerous lesion in the very rare non-HPV-related CSCC ( 48 ).…”

Section: Hpv Attributes Screening Diagnosis Treatment and Preventionmentioning

confidence: 99%

“…Even though p16 expression is considered to be a surrogate marker for HPVassociation, p16 IHC testing is not absolutely necessary for the classification, and HPV analysisis not necessary for the diagnosis ( 48 ). HPV-related CSCC causes pre-cancerous lesions but there is no known precancerous lesion in the very rare non-HPV-related CSCC ( 48 ). Accordingto WHO guidelines, HPV DNA testing is used to detect HPV-related CSCC but p16 IHC is also recommended since morphology alone cannot distinguish the two types ( 48 ).…”

Section: Hpv Attributes Screening Diagnosis Treatment and Preventionmentioning

confidence: 99%

“…HPV-related CSCC causes pre-cancerous lesions but there is no known precancerous lesion in the very rare non-HPV-related CSCC ( 48 ). Accordingto WHO guidelines, HPV DNA testing is used to detect HPV-related CSCC but p16 IHC is also recommended since morphology alone cannot distinguish the two types ( 48 ). Cervical cancer is a continuous single disease process advancing gradually from mild cervical intraepithelial neoplasia (CIN1) to more severe degrees of neoplasia and micro-invasive lesions (CIN2 or CIN3) and finally to invasive disease ( 30 ).…”

Section: Hpv Attributes Screening Diagnosis Treatment and Preventionmentioning

confidence: 99%

See 3 more Smart Citations

Molecular Detection Methods in HPV-Related Cancers

2022

View full text Add to dashboard Cite

Human papillomavirus (HPV) is responsible for most cervical cancers and some head and neck cancers, including oropharyngeal squamous cell carcinoma and sinonasal carcinoma. Cervical cancer is commonly diagnosed by liquid-based cytology, followed by HPV testing using commercially available DNA polymerase chain reaction (PCR), p16 immunohistochemistry (IHC), or DNA/RNA in situ hybridization. HPV in head and neck cancers is commonly diagnosed by p16 IHC or by RT-qPCR of HPV-16 E6 and E7 oncoproteins. Droplet digital PCR has been reported as an ultrasensitive and highly precise method of nucleic acid quantification for biomarker analysis and has been used to detect oncogenic HPV in oropharyngeal and cervical cancers.

show abstract

Section: Hpv Attributes Screening Diagnosis Treatment and Preventionmentioning

confidence: 99%

Section: Hpv Attributes Screening Diagnosis Treatment and Preventionmentioning

confidence: 99%

Section: Hpv Attributes Screening Diagnosis Treatment and Preventionmentioning

confidence: 99%

Section: Hpv Attributes Screening Diagnosis Treatment and Preventionmentioning

confidence: 99%

See 2 more Smart Citations

Molecular Detection Methods in HPV-Related Cancers

2022

View full text Add to dashboard Cite

show abstract

“…Endometrial stromal sarcoma is a rare mesenchymal tumor, accounting for less than 1% of uterine cancers; however, it is the second most common uterine sarcoma, after leiomyosarcoma, comprising 17–25% of cases 1 2. Endometrial stromal tumors are classified into four histopathologic entities—endometrial stromal nodules, low-grade endometrial stromal sarcoma, high-grade endometrial stromal sarcoma, and undifferentiated uterine sarcomas 3. Low-grade endometrial stromal sarcoma is generally characterized by an indolent course and favorable prognosis, with a 5-year overall survival rate of >90% 1 2…”

Section: Introductionmentioning

confidence: 99%

Primary characteristics and outcomes of newly diagnosed low-grade endometrial stromal sarcoma

Smith

Jansen

Miller

et al. 2022

Int J Gynecol Cancer

View full text Add to dashboard Cite

ObjectiveTo assess potential predictive variables for nodal metastasis and survival outcomes in patients with newly diagnosed, low-grade endometrial stromal sarcoma.MethodsWe performed a single-institution, retrospective analysis of consecutive patients with newly diagnosed, low-grade endometrial stromal sarcoma who presented between January 1, 1980 and December 31, 2019 and underwent hysterectomy at our institution or presented within 3 months of primary surgery elsewhere before recurrence. Patients who presented to our institution only at recurrence were excluded. Patients with <3 months of follow-up were excluded from survival analyses.ResultsWe identified 127 consecutive patients for analysis. Median age at diagnosis was 48 years (range 19–88 years); 91 (74.6%) of 127 were pre-menopausal; and 74 (58.3%) of 127 had uterine-confined, stage I tumors. Of 56 patients (44.1%) who underwent lymph node sampling, 10 (17.9%) had nodal metastasis. Of the 10 with nodal metastasis, 1 (10%) did not have lymphadenopathy or extra-uterine disease, 4 (40%) had lymphadenopathy only, 1 (10%) had extra-uterine disease only, and 4 (40%) had both. Among the 29 patients without apparent extra-uterine disease or gross lymphadenopathy, there was one occult lymph node metastasis (3.4%). Gross lymphadenopathy at time of surgery was predictive for lymph node metastasis (p<0.001). Median follow-up was 69 months (range 4–336) for the 95 patients included in the survival analyses. The 5-year progression-free survival and disease-specific survival rates were 79.8% and 90.8%, respectively. Patients with stage I tumors had longer progression-free survival than those with stage II–IV disease (p<0.001); there was no difference in disease-specific survival (p=0.63). Post-operative observation versus adjuvant therapy with hormone blockade or radiation therapy did not result in progression-free survival differences for stage I or completely resected stage II–IV disease (p=0.50 and p=0.81, respectively). Similarly, there was no disease-specific survival difference for completely resected stage II–IV disease (p=0.3).ConclusionsLymph node dissection in patients with low-grade endometrial stromal sarcoma should be reserved for those with clinically suspicious lymphadenopathy. Disease stage correlated with progression-free survival but not disease-specific survival. Post-operative therapy did not improve progression-free survival or disease-specific survival.

show abstract

Molecular pathology and clinical treatment of independent HPV primary serous carcinoma of the uterine cervix (USCC): A case report

Niu,

Ruan,

Yang

et al. 2023

Clinical Case Reports

View full text Add to dashboard Cite

On October 23, 2020, a 69‐year‐old Chinese female patient was admitted to Yuncheng Hospital due to a history of postmenopausal bleeding and lower abdominal pain for 5 months. The HPV test and pathology results indicated the presence of independent HPV in primary serous carcinoma of the uterine cervix. The genetic testing identified variants of uncertain significance (PAX8 p.Tyr 410 Ter and TP53 p.Asn 247 Ile), microsatellite instability stable (MSI‐S), tumor mutational burden (TMB) 7.33Muts/Mb, and an elevated tumor neoantigen burden. Before undergoing radical hysterectomy treatment, the patient exhibited a positive response to three cycles of intravenous docetaxel (100 mg/3 h) and carboplatin (450 mg/1 h). Following the surgery, she received an additional three cycles of docetaxel (100 mg/3 h) and carboplatin (500 mg/1 h), accompanied by 25 cycles of radiation therapy (DT 46Gy/2Gy/23f). Concurrently, cisplatin (450 mg/1 h) was administered. As of now, the patient has achieved 20 months of disease‐free survival.

show abstract

2020 WHO Classification of Female Genital Tumors

Cited by 140 publications

References 42 publications

Molecular Detection Methods in HPV-Related Cancers

Molecular Detection Methods in HPV-Related Cancers

Primary characteristics and outcomes of newly diagnosed low-grade endometrial stromal sarcoma

Molecular pathology and clinical treatment of independent HPV primary serous carcinoma of the uterine cervix (USCC): A case report

Contact Info

Product

Resources

About